Bacterin International Holdings, Inc., an accredited tissue bank and medical device company, has launched OsteoSTX, a new novel allograft for orthopaedic procedures. Utilizing Bacterin's proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multi-level and deformity spinal applications.
"This is the first product Bacterin has launched since I joined the company, and I have been very pleased with the process and the results," said Dan Goldberger, Bacterin president and CEO. "We introduced this product to key opinion leaders at the NASS Evidence and Technology Spine Summit (Park City, UT) and the feedback was astounding. I am looking forward to seeing how distribution of this new product will help support our growth goals, and complement our existing product portfolio."
OsteoSTX is the first product in Bacterin’s biologic portfolio designed specifically for addressing multi-level spine procedures and deformity cases. Bacterin is the first company to market a product of this type for single use application. OsteoSTX has already been implanted in patients with strong surgeon feedback supporting the use of the product and the application.
Bacterin is an accredited tissue bank and medical device company that designs, processes, manufactures, and markets advanced medical products. Using designs focused on efficacy and safety for the patient, and functionality and ease of use for the surgeon, our innovative products fulfill niche needs in the industry.